ORLANDO, Fla., June 28, 2017/PRNewswire/ -- Profounda, Inc. ("Profounda") announced today that it has received the US Food and Drug Administration's Orphan Drug Designation for the use of miltefosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results